- Home
- DBCA vs AUTL Comparison
DBCA vs AUTL Comparison
Compare DBCA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DBCA | AUTL |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.3M | 407.2M |
| IPO Year | 2026 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DBCA | AUTL |
|---|---|---|
| Price | $9.88 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 60.2K | ★ 1.2M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $9.83 | $1.15 |
| 52 Week High | $9.90 | $2.70 |
Technical Indicators
Market Signals| Indicator | DBCA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 56.28 |
| Support Level | $9.86 | $1.22 |
| Resistance Level | $9.90 | $1.69 |
| Average True Range (ATR) | 0.01 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 66.67 | 57.63 |
Price Performance
Historical ComparisonAbout DBCA D. Boral Acquisition I Corp. Class A Ordinary Shares
D Boral Acquisition I Corp is a blank check company. It is formed as a BVI business company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.